Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the drugmaker’s immunology pipeline.
Related Posts
Inside the Business of Running a Haunted House
Most don’t make it past their third year. But the successful ones have figured out a winning formula.
Airbus to Shed 2,500 Jobs in Embattled Defense and Space Division
The cuts come as the company battles with delays, increased costs and competition from the likes of SpaceX.
Elon Musk’s $46 Billion Pay Package: How Tesla Shareholder Approval Could Play Out in Court
- staff
- June 13, 2024
- 0
The carmaker’s CEO says so far, shareholders were approving the package by a wide margin. But a vote to reapprove the agreement is unlikely to […]